Wyniki wyszukiwania

1

Medycyna personalizowana - nowa era diagnostyki i farmakoterapii

100%

Gaciong Z.

Biotechnologia. Monografie

|

2009

|

nr 05

11-17

2

Medycyna personalizowana – dziś i jutro

88%

Gaciong Z.

Diagnostyka Laboratoryjna

|

2017

|

tom 53

|

nr 1A

3

Badania nad pochodzeniem miocytow blony wewnetrznej w przeszczepie aorty allogenicznej u szczura

51%

Religa P., Bojakowski K., Gaciong Z.

Postępy Biologii Komórki. Suplement

|

2003

|

tom 21

97-102

4

Why study sympathetic nervous system?

45%

Sinski M., Lewandowski J., Abramczyk P., Narkiewicz K., Gaciong Z.

Journal of Physiology and Pharmacology. Supplement

|

2006

|

tom 57

|

nr 11

79-92

Cardiovascular diseases are the most frequent causes of morbidity and mortality around the world. However, during last decades, an improvement was made in diagnosis and therapy of cardiovascular diseases, there was still a need for better understanding of their pathophysiology. Among neurohormonal systems, SNS plays a central role in cardiovascular regulation in both health and disease. Involvement of SNS in pathogenesis of hypertension, coronary artery disease or heart failure is well known and proved. Methods such as microneurography, direct catecholamine measurements, heart rate variability or baroreflex sensitivity assessment allowed studying sympathetic activity and its influence on cardiovascular disorders. Although introduced into scientific practice methods of SNS evaluation are not commonly used in the clinic. However, two of the methods: analysis of heart rate variability (HRV) and baroreflex sensitivity (BRS) were recommended as the diagnostic tools and can be found in clinical guidelines as basic assessment methods.

5

TFX modulates the immunosuppressive effect of cyclophosphamide on antibody production in mice

45%

Paczek L., Gaciong Z., Gorski A., Lagodzinski Z., Brzezny M.

Archivum Immunologiae et Therapiae Experimentalis

|

1989

|

tom 37

|

nr 3-4

6

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Fucoidan improves the renal blood flow in the early stage of renal ischemia-reperfusion injury in the rat

39%

Bojakowski K., Abramczyk P., Bojakowska M., Zwolinska A., Przybylski J., Gaciong Z.

Journal of Physiology and Pharmacology

|

2001

|

tom 52

|

nr 1

7

Genetic screening for glucocorticid-remedible aldosteronism [GRA]: experience of three clinical centres in Poland

33%

Adler G., Widecka K., Peczkowska M., Dobrucki T., Placha G., Drozd R., Parczewski M., Januszewicz A., Gaciong Z., Ciechanowicz A.

Journal of Applied Genetics

|

2005

|

tom 46

|

nr 3

329-332

Glucocorticoid-remediable aldosteronism (GRA), also known as familial hyperaldosteronism type I (FH-I, OMIM 103900), is a monogenic form of inherited hypertension caused by the presence of a chimaeric gene originating from an unequal cross-over between the CYP11B1 (11ß-hydroxylase) and CYP11B2 (aldosterone synthase) genes. The hybrid gene has the CYP11B1 sequence at the 5' end, including the promoter, and the CYP11B2 sequence at the 3' end. The aim of our study was to evaluate the prevalence of GRA in a Polish population of 129 patients with primary hyperaldosteronism (PHA) and 132 patients with essential hypertension (EH), through the use of a PCR-based test revealing the chimaeric gene. None of our PHA or EH patients was positive for the CYP11BHCYP11B2 chimaeric gene. These data suggest that GRA is unlikely to be a common cause of hypertension in Polish subjects. However, the real prevalence of GRA in Poland, both in the high-risk group of individuals with primary hyperaldosteronism and in the general population, remains to be established.